ArticleScientific reports2025
Prognostic relevance of TROP2 expression in patients with non-small cell lung cancer receiving immunotherapy.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Association between prognostic nutritional index and prognosis in non-small cell lung cancer patients receiving PD-1/PD-L1 inhibitors: a meta-analysis.Frontiers in nutrition · 2026Pooled it
- Anti-TROP2 Antibody Drug Conjugates in EGFR-Mutant Non-Small Cell Lung Cancer: Biological Rationale and Clinical Challenges.Pharmaceutics · 2026Review
- TROP2 expression as a prognostic predictor for osimertinib in patients withTranslational lung cancer research · 2026Article
- TROP2 expression is associated with early stage and favorable prognosis in upper tract urothelial carcinoma.World journal of urology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Trophoblast surface antigen 2 (TROP2) is strongly expressed in patients with non-small cell lung cancer (NSCLC), and its overexpression is closely associated with a worse prognosis. Recently, a novel TROP2-directed antibody-drug conjugate (ADC) has been developed, and TROP2 has been identified as a therapeutic target for NSCLC. In this study, we investigated whether TROP2 expression can predict the outcome after combined immunotherapy with programmed death-1 (PD-1) blockade plus cytotoxic T-lymphocyte antigen-4 (CTLA4) antibody. The present study included 110 patients with advanced NSCLC who received nivolumab plus ipilimumab (Nivo-Ipi) between 2020 and 2022 at our institution. TROP2 and Ki-67 protein expression were evaluated by immunohistochemistry. Inflammatory and nutritional indices were investigated with several variables, including neutrophil to lymphocyte ratio (NLR), platelet to lymphocyte ratio (PLR), systemic immune-inflammation index (SII), prognostic nutritional index (PNI), advanced lung cancer inflammation index (ALI), and Glasgow prognostic score. TROP2 was highly expressed in 46 (41.8%) patients, and its overexpression was significantly associated with poor response to Nivo-Ipi therapy. Univariate analysis of all patients identified performance status, liver metastases, bone metastases, NLR, TROP2, PLR, SII, PNI, and ALI as significant predictors of progression-free survival (PFS) and overall survival (OS) after Nivo-Ipi treatment. Multivariate analysis identified TROP2 overexpression as an independent prognostic predictor for PFS and OS. Specifically, TROP2 overexpression was significantly associated with shorter PFS and OS in the subgroups of PD-L1 < 1% or non-adenocarcinoma histology. TROP2 expression could be a significant predictor for outcome after Nivo-Ipi treatment in patients with advanced NSCLC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.